仙琚制药(002332.SZ)：签订共同授权合作产品中国境内推广服务之三方协议及相关协议

Core Viewpoint - Xianju Pharmaceutical has established strategic partnerships for the development and commercialization of the drug Aomikson Sodium (also known as Ageng Glucose Sodium Injection) with Hangzhou Aomei Pharmaceutical and Aishijian (Guangdong) Pharmaceutical [1][2] Group 1: Agreements and Collaborations - On December 17, 2015, Xianju Pharmaceutical signed a development cooperation agreement for Aomikson Sodium with Hangzhou Aomei [1] - A supplementary agreement was signed on April 16, 2021, to further the development of Aomikson Sodium [1] - A strategic cooperation framework agreement was signed on January 12, 2023, to outline the collaboration on Aomikson Sodium [1] Group 2: Recent Developments - On January 16, 2026, Xianju Pharmaceutical, Hangzhou Aomei, and Aishijian signed a tripartite agreement to authorize Aishijian as the exclusive marketing service provider for Aomikson Sodium in mainland China [2] - The commercialization milestone sharing ratio for Aomikson Sodium is set at 50% for both Xianju Pharmaceutical and Hangzhou Aomei [2] - A procurement supply agreement and a supplementary agreement for contract manufacturing of Aomikson Sodium were also signed on January 16, 2026 [2]